Release issued 14th October 2004

Ethypharm adds on its existing line of morphine products

Ethypharm, a pharmaceutical technology company, with focus on development of oral modified release products, announced the marketing approval in Denmark of its once-a- day morphine sulfate, which will soon be followed by a Mutual Recognition Procedure in Europe as from Q1 2005..

The new once-a-day formulation is a capsule that contains sustained release microgranules and allow the once-daily treatment of moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time.

"Morphine has a short half-life (2 to 3 hours) when administered orally", said Dr Françoise Vauzelle Kervroëdan, Director of Medical Affairs at Ethypharm. "This means that immediate release formulations must be administered every 4 hours to maintain adequate pain relief. This often results in interrupted sleep and inconvenience for the patient, and the potential for non-compliance or medical errors. This new formulation provides a steady concentration of the drug in the blood, and therefore significantly improves the patient's quality of life, " she added.

Ethypharm provided the market with a real 12 hours morphine sulfate in pellets. It was launched in France in 1992 by UPSA, a Bristol-Myers Company, under the trade name SKENAN® LP. Ethypharm's morphine was also the first twice-a-day formulation based on microgranules to obtain a Marketing Authorisation (M.A.) in Japan in March 2001. This BID formulation was then completed with an immediate- release product - ACTISKENAN® - marketed in France by UPSA.

The approval of the Once-a-day formulation allows Ethypharm to ensure its position as leading provider of products in the treatment of pain with a complete range of morphine products.

The worldwide sustained-release opioid market has grown by an average of 30% annually since 1998. Despite this steady growth, recent studies indicate that as many as 30-85% of select chronic pain patients still are under treated. - END -

About Ethypharm www.ethypharm.com

Ethypharm is a drug delivery company that focuses on oral modified release branded and generic products. Main therapeutic areas include pain management, cardiovascular and CNS. The company has more than 50 products marketed by international partners in approx. 70 countries and is committed to develop and manufacture key products which meet the international pharmaceutical requirements. Ethypharm has a broad range of proprietary platforms including controlled release technology, taste masking and orally disintegrating dosage forms and enhanced solubilisation systems for poorly soluble drugs. Ethypharm is present on all the world's major healthcare markets with manufacturing and R&D operations in Europe, the Americas and Asia. It employs 600 people worldwide.

(13th July 2007) Buprenorphine - Merck Generiques becomes the 2nd partner of Ethypharm in France

(10th April 2007) Astorg Partners leads MBO of Ethypharm alongside management and existing investors

(12th December 2005) Ethypharm announced today changes in its Board of Directors and in the organisation of the company.

(30th September 2004) ETHYPHARM's formulation of Tramadol SR Bid approved in Germany

(8th June 2004) Ethypharm and Kowa enter into Licence and Supply Agreement for two OroDispersibleTablets in Japan. The Two Companies to Develop an Oral Flashtab® Version of Paracetamol and Ibuprofen for Japan.